nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Vasospasm—Carmustine—malignant glioma	0.0358	0.0358	CcSEcCtD
Gadoversetamide—Hyperacusis—Temozolomide—malignant glioma	0.0317	0.0317	CcSEcCtD
Gadoversetamide—Meningitis—Carmustine—malignant glioma	0.0315	0.0315	CcSEcCtD
Gadoversetamide—Myasthenia—Carmustine—malignant glioma	0.0194	0.0194	CcSEcCtD
Gadoversetamide—Parosmia—Temozolomide—malignant glioma	0.0182	0.0182	CcSEcCtD
Gadoversetamide—Burning sensation—Carmustine—malignant glioma	0.0176	0.0176	CcSEcCtD
Gadoversetamide—Vaginal haemorrhage—Temozolomide—malignant glioma	0.016	0.016	CcSEcCtD
Gadoversetamide—Accidental injury—Carmustine—malignant glioma	0.0138	0.0138	CcSEcCtD
Gadoversetamide—Breast pain—Temozolomide—malignant glioma	0.0135	0.0135	CcSEcCtD
Gadoversetamide—Herpes simplex—Temozolomide—malignant glioma	0.0128	0.0128	CcSEcCtD
Gadoversetamide—Neck pain—Carmustine—malignant glioma	0.0124	0.0124	CcSEcCtD
Gadoversetamide—Injection site reaction—Carmustine—malignant glioma	0.0121	0.0121	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Carmustine—malignant glioma	0.0102	0.0102	CcSEcCtD
Gadoversetamide—Ear pain—Temozolomide—malignant glioma	0.01	0.01	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Temozolomide—malignant glioma	0.0099	0.0099	CcSEcCtD
Gadoversetamide—Eye pain—Carmustine—malignant glioma	0.00982	0.00982	CcSEcCtD
Gadoversetamide—Injury—Carmustine—malignant glioma	0.00965	0.00965	CcSEcCtD
Gadoversetamide—Eye pain—Temozolomide—malignant glioma	0.00949	0.00949	CcSEcCtD
Gadoversetamide—Amnesia—Carmustine—malignant glioma	0.00944	0.00944	CcSEcCtD
Gadoversetamide—Nasal congestion—Temozolomide—malignant glioma	0.00941	0.00941	CcSEcCtD
Gadoversetamide—Amnesia—Temozolomide—malignant glioma	0.00912	0.00912	CcSEcCtD
Gadoversetamide—Thirst—Temozolomide—malignant glioma	0.00901	0.00901	CcSEcCtD
Gadoversetamide—Hyponatraemia—Carmustine—malignant glioma	0.0089	0.0089	CcSEcCtD
Gadoversetamide—Diplopia—Carmustine—malignant glioma	0.00887	0.00887	CcSEcCtD
Gadoversetamide—Diplopia—Temozolomide—malignant glioma	0.00857	0.00857	CcSEcCtD
Gadoversetamide—Face oedema—Carmustine—malignant glioma	0.00856	0.00856	CcSEcCtD
Gadoversetamide—Face oedema—Temozolomide—malignant glioma	0.00827	0.00827	CcSEcCtD
Gadoversetamide—Dry skin—Temozolomide—malignant glioma	0.00786	0.00786	CcSEcCtD
Gadoversetamide—Muscular weakness—Carmustine—malignant glioma	0.00782	0.00782	CcSEcCtD
Gadoversetamide—Dysphagia—Carmustine—malignant glioma	0.00766	0.00766	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00756	0.00756	CcSEcCtD
Gadoversetamide—Muscular weakness—Temozolomide—malignant glioma	0.00756	0.00756	CcSEcCtD
Gadoversetamide—Dysphagia—Temozolomide—malignant glioma	0.00741	0.00741	CcSEcCtD
Gadoversetamide—Sweating increased—Temozolomide—malignant glioma	0.00722	0.00722	CcSEcCtD
Gadoversetamide—Dysuria—Temozolomide—malignant glioma	0.00693	0.00693	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Carmustine—malignant glioma	0.00691	0.00691	CcSEcCtD
Gadoversetamide—Pneumonia—Carmustine—malignant glioma	0.00687	0.00687	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Temozolomide—malignant glioma	0.00668	0.00668	CcSEcCtD
Gadoversetamide—Urinary tract infection—Carmustine—malignant glioma	0.00664	0.00664	CcSEcCtD
Gadoversetamide—Pneumonia—Temozolomide—malignant glioma	0.00664	0.00664	CcSEcCtD
Gadoversetamide—Urinary tract infection—Temozolomide—malignant glioma	0.00642	0.00642	CcSEcCtD
Gadoversetamide—Sinusitis—Temozolomide—malignant glioma	0.0062	0.0062	CcSEcCtD
Gadoversetamide—Haemoglobin—Carmustine—malignant glioma	0.00617	0.00617	CcSEcCtD
Gadoversetamide—Haemorrhage—Carmustine—malignant glioma	0.00614	0.00614	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Carmustine—malignant glioma	0.0061	0.0061	CcSEcCtD
Gadoversetamide—Hallucination—Carmustine—malignant glioma	0.0061	0.0061	CcSEcCtD
Gadoversetamide—Oedema peripheral—Carmustine—malignant glioma	0.00604	0.00604	CcSEcCtD
Gadoversetamide—Haemoglobin—Temozolomide—malignant glioma	0.00596	0.00596	CcSEcCtD
Gadoversetamide—Haemorrhage—Temozolomide—malignant glioma	0.00593	0.00593	CcSEcCtD
Gadoversetamide—Hallucination—Temozolomide—malignant glioma	0.0059	0.0059	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Temozolomide—malignant glioma	0.0059	0.0059	CcSEcCtD
Gadoversetamide—Pharyngitis—Temozolomide—malignant glioma	0.00588	0.00588	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Temozolomide—malignant glioma	0.00586	0.00586	CcSEcCtD
Gadoversetamide—Oedema peripheral—Temozolomide—malignant glioma	0.00584	0.00584	CcSEcCtD
Gadoversetamide—Urethral disorder—Temozolomide—malignant glioma	0.00581	0.00581	CcSEcCtD
Gadoversetamide—Eye disorder—Carmustine—malignant glioma	0.00573	0.00573	CcSEcCtD
Gadoversetamide—Flushing—Carmustine—malignant glioma	0.00569	0.00569	CcSEcCtD
Gadoversetamide—Erythema multiforme—Temozolomide—malignant glioma	0.00561	0.00561	CcSEcCtD
Gadoversetamide—Eye disorder—Temozolomide—malignant glioma	0.00554	0.00554	CcSEcCtD
Gadoversetamide—Tinnitus—Temozolomide—malignant glioma	0.00553	0.00553	CcSEcCtD
Gadoversetamide—Cardiac disorder—Temozolomide—malignant glioma	0.0055	0.0055	CcSEcCtD
Gadoversetamide—Flushing—Temozolomide—malignant glioma	0.0055	0.0055	CcSEcCtD
Gadoversetamide—Arrhythmia—Carmustine—malignant glioma	0.00548	0.00548	CcSEcCtD
Gadoversetamide—Angiopathy—Temozolomide—malignant glioma	0.00538	0.00538	CcSEcCtD
Gadoversetamide—Mental disorder—Carmustine—malignant glioma	0.00537	0.00537	CcSEcCtD
Gadoversetamide—Immune system disorder—Temozolomide—malignant glioma	0.00536	0.00536	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Temozolomide—malignant glioma	0.00534	0.00534	CcSEcCtD
Gadoversetamide—Malnutrition—Carmustine—malignant glioma	0.00534	0.00534	CcSEcCtD
Gadoversetamide—Erythema—Carmustine—malignant glioma	0.00534	0.00534	CcSEcCtD
Gadoversetamide—Chills—Temozolomide—malignant glioma	0.00532	0.00532	CcSEcCtD
Gadoversetamide—Mental disorder—Temozolomide—malignant glioma	0.00519	0.00519	CcSEcCtD
Gadoversetamide—Back pain—Carmustine—malignant glioma	0.00517	0.00517	CcSEcCtD
Gadoversetamide—Malnutrition—Temozolomide—malignant glioma	0.00516	0.00516	CcSEcCtD
Gadoversetamide—Erythema—Temozolomide—malignant glioma	0.00516	0.00516	CcSEcCtD
Gadoversetamide—Dysgeusia—Temozolomide—malignant glioma	0.00505	0.00505	CcSEcCtD
Gadoversetamide—Vision blurred—Carmustine—malignant glioma	0.00503	0.00503	CcSEcCtD
Gadoversetamide—Tremor—Carmustine—malignant glioma	0.005	0.005	CcSEcCtD
Gadoversetamide—Back pain—Temozolomide—malignant glioma	0.00499	0.00499	CcSEcCtD
Gadoversetamide—Agitation—Carmustine—malignant glioma	0.00491	0.00491	CcSEcCtD
Gadoversetamide—Vision blurred—Temozolomide—malignant glioma	0.00486	0.00486	CcSEcCtD
Gadoversetamide—Tremor—Temozolomide—malignant glioma	0.00484	0.00484	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Temozolomide—malignant glioma	0.00479	0.00479	CcSEcCtD
Gadoversetamide—Agitation—Temozolomide—malignant glioma	0.00474	0.00474	CcSEcCtD
Gadoversetamide—Malaise—Temozolomide—malignant glioma	0.00465	0.00465	CcSEcCtD
Gadoversetamide—Vertigo—Temozolomide—malignant glioma	0.00464	0.00464	CcSEcCtD
Gadoversetamide—Convulsion—Carmustine—malignant glioma	0.00463	0.00463	CcSEcCtD
Gadoversetamide—Hypertension—Carmustine—malignant glioma	0.00461	0.00461	CcSEcCtD
Gadoversetamide—Palpitations—Temozolomide—malignant glioma	0.00456	0.00456	CcSEcCtD
Gadoversetamide—Chest pain—Carmustine—malignant glioma	0.00455	0.00455	CcSEcCtD
Gadoversetamide—Myalgia—Carmustine—malignant glioma	0.00455	0.00455	CcSEcCtD
Gadoversetamide—Anxiety—Carmustine—malignant glioma	0.00453	0.00453	CcSEcCtD
Gadoversetamide—Cough—Temozolomide—malignant glioma	0.0045	0.0045	CcSEcCtD
Gadoversetamide—Convulsion—Temozolomide—malignant glioma	0.00447	0.00447	CcSEcCtD
Gadoversetamide—Hypertension—Temozolomide—malignant glioma	0.00446	0.00446	CcSEcCtD
Gadoversetamide—Confusional state—Carmustine—malignant glioma	0.00439	0.00439	CcSEcCtD
Gadoversetamide—Myalgia—Temozolomide—malignant glioma	0.00439	0.00439	CcSEcCtD
Gadoversetamide—Arthralgia—Temozolomide—malignant glioma	0.00439	0.00439	CcSEcCtD
Gadoversetamide—Anxiety—Temozolomide—malignant glioma	0.00438	0.00438	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00436	0.00436	CcSEcCtD
Gadoversetamide—Oedema—Carmustine—malignant glioma	0.00436	0.00436	CcSEcCtD
Gadoversetamide—Discomfort—Temozolomide—malignant glioma	0.00434	0.00434	CcSEcCtD
Gadoversetamide—Dry mouth—Temozolomide—malignant glioma	0.0043	0.0043	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Carmustine—malignant glioma	0.00427	0.00427	CcSEcCtD
Gadoversetamide—Tachycardia—Carmustine—malignant glioma	0.00425	0.00425	CcSEcCtD
Gadoversetamide—Confusional state—Temozolomide—malignant glioma	0.00425	0.00425	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Temozolomide—malignant glioma	0.00421	0.00421	CcSEcCtD
Gadoversetamide—Oedema—Temozolomide—malignant glioma	0.00421	0.00421	CcSEcCtD
Gadoversetamide—Anorexia—Carmustine—malignant glioma	0.00415	0.00415	CcSEcCtD
Gadoversetamide—Nervous system disorder—Temozolomide—malignant glioma	0.00413	0.00413	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Temozolomide—malignant glioma	0.00412	0.00412	CcSEcCtD
Gadoversetamide—Skin disorder—Temozolomide—malignant glioma	0.00409	0.00409	CcSEcCtD
Gadoversetamide—Hypotension—Carmustine—malignant glioma	0.00407	0.00407	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Temozolomide—malignant glioma	0.00407	0.00407	CcSEcCtD
Gadoversetamide—Anorexia—Temozolomide—malignant glioma	0.00402	0.00402	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00397	0.00397	CcSEcCtD
Gadoversetamide—Insomnia—Carmustine—malignant glioma	0.00394	0.00394	CcSEcCtD
Gadoversetamide—Paraesthesia—Carmustine—malignant glioma	0.00391	0.00391	CcSEcCtD
Gadoversetamide—Dyspnoea—Carmustine—malignant glioma	0.00389	0.00389	CcSEcCtD
Gadoversetamide—Somnolence—Carmustine—malignant glioma	0.00387	0.00387	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00384	0.00384	CcSEcCtD
Gadoversetamide—Insomnia—Temozolomide—malignant glioma	0.00381	0.00381	CcSEcCtD
Gadoversetamide—Decreased appetite—Carmustine—malignant glioma	0.00379	0.00379	CcSEcCtD
Gadoversetamide—Paraesthesia—Temozolomide—malignant glioma	0.00378	0.00378	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Carmustine—malignant glioma	0.00376	0.00376	CcSEcCtD
Gadoversetamide—Dyspnoea—Temozolomide—malignant glioma	0.00376	0.00376	CcSEcCtD
Gadoversetamide—Somnolence—Temozolomide—malignant glioma	0.00374	0.00374	CcSEcCtD
Gadoversetamide—Pain—Carmustine—malignant glioma	0.00373	0.00373	CcSEcCtD
Gadoversetamide—Constipation—Carmustine—malignant glioma	0.00373	0.00373	CcSEcCtD
Gadoversetamide—Dyspepsia—Temozolomide—malignant glioma	0.00371	0.00371	CcSEcCtD
Gadoversetamide—Decreased appetite—Temozolomide—malignant glioma	0.00366	0.00366	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00364	0.00364	CcSEcCtD
Gadoversetamide—Fatigue—Temozolomide—malignant glioma	0.00363	0.00363	CcSEcCtD
Gadoversetamide—Pain—Temozolomide—malignant glioma	0.0036	0.0036	CcSEcCtD
Gadoversetamide—Constipation—Temozolomide—malignant glioma	0.0036	0.0036	CcSEcCtD
Gadoversetamide—Feeling abnormal—Carmustine—malignant glioma	0.00359	0.00359	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Carmustine—malignant glioma	0.00356	0.00356	CcSEcCtD
Gadoversetamide—Feeling abnormal—Temozolomide—malignant glioma	0.00347	0.00347	CcSEcCtD
Gadoversetamide—Body temperature increased—Carmustine—malignant glioma	0.00345	0.00345	CcSEcCtD
Gadoversetamide—Abdominal pain—Carmustine—malignant glioma	0.00345	0.00345	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Temozolomide—malignant glioma	0.00344	0.00344	CcSEcCtD
Gadoversetamide—Urticaria—Temozolomide—malignant glioma	0.00335	0.00335	CcSEcCtD
Gadoversetamide—Abdominal pain—Temozolomide—malignant glioma	0.00333	0.00333	CcSEcCtD
Gadoversetamide—Body temperature increased—Temozolomide—malignant glioma	0.00333	0.00333	CcSEcCtD
Gadoversetamide—Hypersensitivity—Carmustine—malignant glioma	0.00321	0.00321	CcSEcCtD
Gadoversetamide—Asthenia—Carmustine—malignant glioma	0.00313	0.00313	CcSEcCtD
Gadoversetamide—Hypersensitivity—Temozolomide—malignant glioma	0.0031	0.0031	CcSEcCtD
Gadoversetamide—Asthenia—Temozolomide—malignant glioma	0.00302	0.00302	CcSEcCtD
Gadoversetamide—Diarrhoea—Carmustine—malignant glioma	0.00298	0.00298	CcSEcCtD
Gadoversetamide—Pruritus—Temozolomide—malignant glioma	0.00298	0.00298	CcSEcCtD
Gadoversetamide—Dizziness—Carmustine—malignant glioma	0.00288	0.00288	CcSEcCtD
Gadoversetamide—Diarrhoea—Temozolomide—malignant glioma	0.00288	0.00288	CcSEcCtD
Gadoversetamide—Dizziness—Temozolomide—malignant glioma	0.00279	0.00279	CcSEcCtD
Gadoversetamide—Vomiting—Carmustine—malignant glioma	0.00277	0.00277	CcSEcCtD
Gadoversetamide—Rash—Carmustine—malignant glioma	0.00275	0.00275	CcSEcCtD
Gadoversetamide—Dermatitis—Carmustine—malignant glioma	0.00275	0.00275	CcSEcCtD
Gadoversetamide—Headache—Carmustine—malignant glioma	0.00273	0.00273	CcSEcCtD
Gadoversetamide—Vomiting—Temozolomide—malignant glioma	0.00268	0.00268	CcSEcCtD
Gadoversetamide—Rash—Temozolomide—malignant glioma	0.00266	0.00266	CcSEcCtD
Gadoversetamide—Dermatitis—Temozolomide—malignant glioma	0.00265	0.00265	CcSEcCtD
Gadoversetamide—Headache—Temozolomide—malignant glioma	0.00264	0.00264	CcSEcCtD
Gadoversetamide—Nausea—Carmustine—malignant glioma	0.00259	0.00259	CcSEcCtD
Gadoversetamide—Nausea—Temozolomide—malignant glioma	0.0025	0.0025	CcSEcCtD
